Clinical Trial

Simple Crossover Versus Side Branch Opening in Patients With Non-Left Main Bifurcation Lesion

Study acronym: CROSS-COBIS
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Hypothesis: Simple crossover strategy would be non-inferior to SB opening strategy in the risk of target lesion failure (TLF) in patients with angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion. A total of 1000 patients (500 per each group) with the angiographically compromised SB (visually SB stenosis ≥50%) after provisional MV stenting for non-left main bifurcation lesion will be enrolled. Patients will be randomized to either the simple crossover strategy group or SB opening strategy group at the time of enrollment with 1:1 ratio. Stratified randomization according to participating center, clinical presentation (acute coronary syndrome or stable ischemic heart disease), and type of bifurcation lesions (true or non-true) will be performed.
Trial Details
NCT Number NCT05705362
Lead Sponsor Keimyung University Dongsan Medical Center
Conditions Coronary Artery Disease
Enrollment 1,000 participants
Start Date 2023-03-01
Primary Completion 2028-03-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-01-30